{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:04:07Z","timestamp":1784563447688,"version":"3.55.0"},"reference-count":38,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article reviews data encompassing the pharmacology, efficacy, and safety of RSVpreF (Abrysvo\u00ae), a subunit vaccine approved to prevent respiratory syncytial virus (RSV) in adults aged \u226560 years, infants via maternal transfer of antibodies, and adults aged 18 to 59 at increased risk of severe disease, including immunocompromised populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature review was conducted in PubMed, MEDLINE, National Institutes of Health Clinical Trials Registry, and ClinicalTrials.gov from inception through May 2026, using the search terms Abrysvo, RSVpreF, RSV vaccine, and respiratory syncytial virus. Articles from reference lists were included to identify potentially relevant literature. Guidance documents, including Food and Drug Administration (FDA) briefing documents, package inserts, and recommendations from Advisory Committee on Immunization Practices were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Data were limited to human clinical studies published in the English language, which evaluated the efficacy, immunogenicity, and safety of RSVpreF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Eight studies are included describing RSVpreF, consisting of 1 phase I, 2 phase II, 4 phase III, and 1 phase IV clinical study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents:<\/jats:title>\n                    <jats:p>To protect vulnerable infants, maternal immunization is recommended as a single dose between 32 and 36 weeks of gestation, typically from September through January. Current clinical guidance recommends vaccination for all adults aged \u226575, and those aged 60 to 74 with one or more risk factors for severe RSV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>RSVpreF provides protection against RSV for older adults, high-risk\/immunocompromised populations, and infants via maternal transfer. RSVpreF effectively reduces the incidence of severe lower respiratory tract infections, bronchiolitis, and hospitalizations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261456670","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T10:52:28Z","timestamp":1782643948000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["RSVpreF: A Vaccine for the Respiratory Syncytial Virus"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-2108","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Genovese","sequence":"additional","affiliation":[{"name":"Florida State University College of Medicine, Tallahassee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-938X","authenticated-orcid":false,"given":"Eric F.","family":"Egelund","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA"},{"name":"Infectious Disease Pharmacokinetics Laboratory, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa752"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.4954"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12101259"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac300"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.0212"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7214a1"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47757-9"},{"key":"e_1_3_2_10_2","unstructured":"Centers for Disease Control and Prevention. RSV-NET: respiratory syncytial virus hospitalization surveillance network. Accessed April 1 2026. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/rsv-net.html"},{"key":"e_1_3_2_11_2","unstructured":"Centers for Disease Control and Prevention. RSV vaccine guidance for pregnant women. Accessed April 1 2026. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/pregnant-people.html"},{"key":"e_1_3_2_12_2","unstructured":"American Lung Association. RSV prevention and treatment. American Lung Association. Published September 12 2025. Accessed January 11 2026. https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/rsv\/treatment"},{"key":"e_1_3_2_13_2","unstructured":"Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV). Symptoms and Care. Accessed July 22 2023. https:\/\/www.cdc.gov\/rsv\/about\/symptoms.html"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213836"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00291-2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106062"},{"key":"e_1_3_2_17_2","unstructured":"GSK. US FDA approves GSK\u2019s Arexvy the world\u2019s first respiratory syncytial virus (RSV) vaccine for older adults [Press Release]. Accessed July 24 2023. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults\/"},{"key":"e_1_3_2_18_2","unstructured":"FDA. U.S. FDA approves ABRYSVO\u2122 Pfizer\u2019s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults [Press Release]. Accessed July 24 2023. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-abrysvotm-pfizers-vaccine-prevention#:~:text=(NYSE%3A%20PFE)%20announced%20today individuals%2060%20years%20and%20olde"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116154"},{"key":"e_1_3_2_20_2","unstructured":"Pfizer announces positive top-line data from phase 3 trial of older adults for its bivalent respiratory syncytial virus (RSV) vaccine candidate. Accessed July 31 2023. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-data-phase-3-trial-older"},{"key":"e_1_3_2_21_2","unstructured":"Food and Drug Administration. Vaccines and related biological products advisory committee meeting: RSVpreF (Abrysvo) briefing document. Published May 18 2023. Accessed January 30 2026. https:\/\/www.fda.gov\/media\/168185\/download"},{"key":"e_1_3_2_22_2","unstructured":"Novavax annnounces topline RSV F vaccine data from two clinical trials in older adults [Press Release]. Accessed May 12 2024. https:\/\/ir.novavax.com\/press-releases\/2016-09-25-Novavax-Announces-Topline-RSV-F-Vaccine-Data-from-Two-Clinical-Trials-in-Older-Adults"},{"key":"e_1_3_2_23_2","unstructured":"A phase 3 protocol to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion F subunit vaccine (RSVpreF) in adults at high risk of severe RSV disease (NCT05842967; Pfizer; started May 11 2023; completed March 18 2024.). ClinicalTrials.gov. Accessed January 14 2026. https:\/\/clinicaltrials.gov\/study\/NCT05842967"},{"key":"e_1_3_2_24_2","unstructured":"A comparison of immunogenicity of licensed RSV vaccines in residents of Long-Term Care Facilities (LTCF) to community-dwelling older adults (NCT06077149; University of Rochester; started November 7 2023; completed November 1 2024). ClinicalTrials.gov. Accessed January 14 2026. https:\/\/clinicaltrials.gov\/study\/NCT06077149"},{"key":"e_1_3_2_25_2","unstructured":"Respiratory syncytial virus vaccine (ABRYSVO) for injection [package insert]. U.S. Food and Drug Administration. Published December 2025. Accessed January 14 2026. https:\/\/www.fda.gov\/media\/168889\/download"},{"key":"e_1_3_2_26_2","unstructured":"A phase 3 multicenter parallel-group open-label study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion F subunit vaccine when coadministered with herpes zoster subunit vaccine in adults \u226550 years of age (NCT06890416; Pfizer; started April 4 2025; estimated completion September 18 2025). ClinicalTrials.gov. Accessed January 14 2026. https:\/\/clinicaltrials.gov\/study\/NCT06890416"},{"key":"e_1_3_2_27_2","unstructured":"A phase 1 open-label age-descending dose-finding study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus Prefusion F subunit vaccine (RSVpreF) in children 2 to <18 years of age (NCT05900154; Pfizer; started June 22 2023; completed February 29 20240). ClinicalTrials.gov. Accessed January 14 2026. https:\/\/clinicaltrials.gov\/study\/NCT05900154"},{"key":"e_1_3_2_28_2","unstructured":"ClinicalTrials.gov. A study of a RSV vaccine when given together with Tdap in healthy nonpregnant women aged between 18 to 49 years. Identifier NCT04071158. Published February 15 2021. Accessed February 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT04071158"},{"issue":"2","key":"e_1_3_2_29_2","first-page":"392","article-title":"Herd immunity: a brief review","volume":"25","author":"Alam MJ","year":"2016","unstructured":"Alam MJ, Rahman MF. Herd immunity: a brief review. Mymensingh Med J. 2016;25(2):392-395.","journal-title":"Mymensingh Med J"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.7748\/paed.8.1.28.s20"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704507114"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.1086"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3928\/00989134-20240207-02"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.013"},{"key":"e_1_3_2_35_2","unstructured":"Centers for Disease Control and Prevention. RSV vaccine guidance for adults. Accessed February 28 2026. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/adults.html"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005551"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7241e1"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91.s1.05"},{"key":"e_1_3_2_39_2","unstructured":"American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination. Accessed April 1 2026. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2023\/09\/maternal-respiratory-syncytial-virus-vaccination"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261456670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261456670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261456670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:17:08Z","timestamp":1782818228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261456670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":38,"alternative-id":["10.1177\/10600280261456670"],"URL":"https:\/\/doi.org\/10.1177\/10600280261456670","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"article-number":"10600280261456670"}}